ArticleFrontiers in immunology2025

Disproportionality analysis of satralizumab in FDA adverse event reporting system and Japanese adverse drug event report: a pharmacovigilance study.

Linhai Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.